Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 100 of 217 entries
View as:

To Decrease Fatigue With Light Therapy

Phase: N/A Priority: Normal
NCT ID: NCT03242902 Org: User:
Start: 09/20/17 End: 08/11/20 Due: 08/11/21

Checkpoint Inhibition and Chemoradiotherapy as Bladder Sparing Treatment in UC

Phase: N/A Priority: Normal
NCT ID: NCT05200988 Org: User:
Start: 03/14/22 End: 09/05/27 Due: 09/05/28

18F-PD-L1 PET/CT in Nivolumab Treated Patients With NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT03564197 Org: User:
Start: 10/25/18 End: 12/30/24 Due: 12/30/25

The Prospective Observational COMPRAYA Cohort Study

Phase: N/A Priority: Normal
NCT ID: NCT04682470 Org: User:
Start: 06/18/21 End: 06/30/35 Due: 06/30/36

Vinorelbine in Advanced BRAF-like Colon Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03482362 Org: User:
Start: 03/01/18 End: 03/01/20 Due: 03/01/21

Circulating Tumor Cells and Cytology in Cerebrospinal Fluid of Patients Clinically Suspected for Leptomeningeal Metastases

Phase: N/A Priority: Normal
NCT ID: NCT01713699 Org: User:
Start: 09/30/12 End: 09/19/17 Due: 09/19/18

Multicentric Randomised Trial for Resectable Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02931890 Org: User:
Start: 12/21/17 End: 03/31/29 Due: 03/31/30

A Platform of Patient Derived Xenografts (PDX) and 2D/3D Cell Cultures of Soft Tissue Sarcomas (STS)

Phase: N/A Priority: Normal
NCT ID: NCT02910895 Org: User:
Start: 09/09/17 End: 09/30/24 Due: 09/30/25

Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02450656 Org: User:
Start: 06/30/15 End: 12/31/19 Due: 12/31/20

Effects of Rapid Genetic Counseling and Testing in Newly Diagnosed Breast Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT00783822 Org: User:
Start: 11/30/08 End: 03/31/12 Due: 03/31/13

Docetaxel Versus Intercalated Erlotinib-docetaxel in Patients With Relapsed EGFR Wild Type, ALK Negative Non Squamous Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT02775006 Org: User:
Start: 10/14/16 End: 04/30/19 Due: 04/30/20

The Development of a Personalized Decision Aid: Perspectives of Patients and Health Care Professionals on Shared Decision Making and Informational Needs on Radiotherapy for Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02934126 Org: User:
Start: 09/30/16 End: 12/28/16 Due: 12/28/17

Use of Individual Pharmacokinetically (PK)-Guided Sunitinib Dosing: A Feasibility Study in Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01286896 Org: User:
Start: 03/31/11 End: 12/31/11 Due: 12/31/12

Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab

Phase: N/A Priority: Normal
NCT ID: NCT02977052 Org: User:
Start: 11/24/16 End: 06/30/25 Due: 06/30/26

Cardiac Changes After Stereotactic Radiotherapy for Early Stage NSCLC Cancer or Lung Metastasis

Phase: N/A Priority: Normal
NCT ID: NCT03984019 Org: User:
Start: 01/13/21 End: 04/01/23 Due: 04/01/24

Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03126812 Org: User:
Start: 11/01/17 End: 03/05/24 Due: 03/05/25

Assess the Safety of Immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the Treatment

Phase: N/A Priority: Normal
NCT ID: NCT04287894 Org: User:
Start: 12/28/18 End: 11/04/24 Due: 11/04/25

Clinical and Pharmacological Study With 2B3-101 in Patients With Breast Cancer and Leptomeningeal Metastases

Phase: N/A Priority: Normal
NCT ID: NCT01818713 Org: User:
Start: 10/31/13 End: 10/31/14 Due: 10/31/15

Organ Preservation in Rectal Cancer: Contact X-ray Brachytherapy vs Extending the Waiting Interval and Local Excision

Phase: N/A Priority: Normal
NCT ID: NCT05772923 Org: User:
Start: 04/16/21 End: 03/31/29 Due: 03/31/30

Standard Moderately Hypofractionated RT vs. Ultra-hypofractionated Focal Lesion Ablative Microboost in Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05705921 Org: User:
Start: 04/26/23 End: 01/01/32 Due: 01/01/33

Blood Sampling of Healthy Volunteers for Immunological Research

Phase: N/A Priority: Normal
NCT ID: NCT03819829 Org: User:
Start: 02/05/19 End: 12/02/27 Due: 12/02/28

Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT04133948 Org: User:
Start: 01/07/20 End: 11/26/24 Due: 11/26/25

Study Comparing Pembrolizumab With Dual MAPK Pathway Inhibition Plus Pembrolizumab in Melanoma Patients

Phase: N/A Priority: Normal
NCT ID: NCT02625337 Org: User:
Start: 01/31/16 End: 12/31/18 Due: 12/31/19

Health After eaRly Menopause Due to Oophorectomy

Phase: N/A Priority: Normal
NCT ID: NCT03835793 Org: User:
Start: 02/11/19 End: 01/01/22 Due: 01/01/23

Nivolumab in Patients With Recurrent Malignant Mesothelioma

Phase: N/A Priority: Normal
NCT ID: NCT02497508 Org: User:
Start: 07/31/15 End: 07/31/17 Due: 07/31/18